tirzepatide cardiovascular outcomes study 💉 In a large real-world study, was associated with a lower incidence of major vs semaglutide: 📊 Composite CV outcome: 1.90% vs 2.18% (HR 0.86, p=0.01) ❤️ New-onset heart tirzepatide cardiovascular outcomes trial results
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13




























